Biocon’s Bengaluru Biosimilars Plant Cleared For EU

Company Expands Production Capacity For Pegfilgrastim And Trastuzumab

 
• By Akriti Seth

Biocon is actively expanding its biosimilars manufacturing capacity with an aim to further penetrate EU markets after receiving a GMP approval for a key manufacturing site. The company has ramped up production for trastuzumab and pegfilgrastim, while awaiting approval for bevacizumab.

GMP concept cell background 3d illustration
After receiving GMP approval for its manufacturing sites, Biocon will further focus on EU markets • Source: Shutterstock

More from Manufacturing

More from Business